Sign in
TerminatedNo phase

Validation of a Prognostic Score for Good Visual Recovery at One Year Following Combined Surgery for Cataract and Idiopathic Epiretinal Membrane

Key facts

Who runs it
Centre Hospitalier Universitaire Dijon
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
164 people enrolled
Started
3 Apr 2018
Ended
5 Jan 2026
Type of study
Observational
Treatments tested
  • measurement of visual acuity
Record updated
4 February 2026
Why it stopped
due to lack of recruitment

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Patients presenting idiopathic ERM visible on SD-OCT
  • Indication for combined cataract and ERM surgery in a context of a fall in visual acuity or disabling metamorphopsia
  • Patients who have provided verbal consent
  • Age ≥ 40 years

Who cannot take part

  • Patients with secondary ERM (Diabetes WITH a history of diabetic retinopathy or maculopathy, occlusion of the retinal veins, uveitis intermediate/posterior uveitis or retinal tear/detachment in the studied eye
  • Patients presenting any other ophthalmological disease independent of the ERM and likely to limit visual acuity
  • Patient présentant toute autre maculopathie ou neuropathie optique
  • Patient presenting severe myopia (spherical equivalent ≥ 6 diopters or axial length ≥ 26 mm)
  • Patients who have already undergone vitrectomy in the studied eye
  • Non-visible or poorly visible fundus due to a cloudy vitreous (Signal on OCT Cirrus <5, Quality score on OCT Spectralis < 20, signal trend index on OCT Optovue < 30)
  • Patients without national health insurance cover
  • Pregnant or breast-feeding women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The prevalence of idiopathic epiretinal membranes (ERM) in people over 50 is estimated at 6 to 19%. Even though most cases show very few symptomats, they may induce alterations of the underlying retina and lead to visual impairment likely to greatly diminish quality of life in patients. Thanks to the ever-improving quality of vitreo-retinal surgery, ablation of these membranes is a frequent and safe procedure allowing a functional gain in the majority of cases. Given the increasing prevalence in the population concerned and the accelerated ageing of the lens after vitrectomy, cataract surgery is often associated with removal of the membrane. On the basis of a study in 142 patients, it was possible to identify clinical and morphological prognostic factors and to inclure them in a score to assess the chances of complete functional recovery at one year following the procedure . Age of the patient, the duration of symptoms, initial visual acuity and the quality of the junction between external and internal segments of photoreceptors in optic coherence tomography (OCT) appeared as significantly related to visual results. Using this score in a new prospective cohort would allow the investigators to make it a reliable and easy-to-use tool at the service of ophthalmologist surgeons and their patients and would provide scientific confirmation of the interest of earlier surgery in this disease. It would also allow the investigators to define in a validated and reproducible manner, a threshold for an ndication for ERM surgery, which is currently based on relatively subjective criteria mostly related to visual acuity.

The group in the trial

  • patient

    any person about to undergo combined surgery for cataract and ERM

    Treatment: measurement of visual acuity

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 February 2026